| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO And President | Chief R&D Commercial Officer
1 company
Khan Najat is a CEO And President at Recursion Pharmaceuticals, Inc.. Recent SEC Form 4 filings include 0 buys and 3 sells.
Estimated insider holdings value: $7.2M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | RXRX Recursion Pharmaceuticals, Inc. | CEO And President | Sell | 28,298 | $3.35 | $94,659.64 | -1.2% | +2.8% | - | |
| Dec 22, 2025 | RXRX Recursion Pharmaceuticals, Inc. | Chief R&D Commercial Officer | Sell | 124,403 | $4.41 | $548,592.35 | -16.9% | -26.6% | - | |
| Aug 18, 2025 | RXRX Recursion Pharmaceuticals, Inc. | Chief R&D Commercial Officer | Sell | 36,599 | $5.52 | $202,172.88 | -5.2% | -25.4% | - |